Novo Nordisk remains a compelling long-term healthcare compounder, despite mixed Q3 results and recent stock weakness. NVO's growth is driven by global obesity drug demand, robust pipeline development ...

Novo Nordisk A/S Chairman Helge Lund is stepping down after a boardroom dispute over the pace of change and will be replaced by Lars Rebien Sorensen, a previous leader of the Danish drugmaker who now ...

Novo Nordisk A/S Chairman Helge Lund is stepping down after a boardroom dispute over governance and will be replaced by Lars Rebien Sorensen, a previous leader of the company who now heads its biggest ...

Novo Nordisk NOVO B announced plans on Oct. 9 to acquire Akero Therapeutics and its phase 3 FGF21 analog efruxifermin for USD 4.7 billion upfront and a potential additional USD 500 million contingent ...

Novo Nordisk's Wegovy will soon come in a pill form that's as effective as with a needle. A new study shows Wegovy taken once a day as a pill helps some patients lose 20% of their body weight. Pills ...

Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk created the ...

Novo Nordisk A/S is working on a strategy to make obesity treatment more personalized and wants to offer options for every kind of patient. The Danish company envisions a trajectory of treatment that ...

Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it is cutting 9,000 jobs, or 11% of its workforce, amid increased competition for obesity medications. The ...

Despite boasting a new owner, the Indiana manufacturing plant Novo Nordisk picked up as part of its parent company's Catalent buyout last year continues to catch flak from the FDA. Novo has received ...

Novo Nordisk scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the U.S. company is using “deceptive marketing” to sell copycat versions of its obesity blockbuster ...

I remember being in a college pathology class when the professor told us we should learn about type 1 diabetes, since it was likely to impact someone we knew. Then he said something else that I didn’t ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and other ...